Newsfeeds - Spark Newswire

3 minute read

Mid-Morning Market Update: Markets Edge Lower; RPM International Posts Mixed Q2 Results

January 5, 11:13 AM

Following the market opening Wednesday, the Dow traded down 0.02% to 36,792.88 while the NASDAQ fell 0.47% to 15,549.51. The S&P also fell, dropping 0.14% to 4,786.96.

AACG

1 minute read

Annexon’s Interim Mid-Stage Results On Huntington’s Disease Candidate Fails To Cheer

By Vandana Singh

January 5, 7:33 AM

Annexon Inc (NASDAQ: ANNX)

ANNX

3 minute read

Annexon Biosciences Reports Interim Phase 2 Data Showing ANX005 ‘Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF’

By Bill Haddad

January 4, 5:09 PM

ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable Patients and 75% of Evaluable

ANNX

4 minute read

Stocks Hitting New 52-Week Lows Today

By Benzinga Insights

January 3, 2:35 PM

On Monday morning, 60 companies achieved new lows for the year.

AGIL

3 minute read

FDA
News

Annexon Biosciences Announces Clinical, Preclinical Data Highlighting Potential Of Complement-Targeting Programs At ASH 2021 Meeting

By Benzinga Newsdesk

December 13, 10:19 AM

Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and

ANNX

4 minute read

52 Biggest Movers From Yesterday

By Lisa Levin

December 1, 5:08 AM

ACET

1 minute read

HC Wainwright & Co. Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $40

By Benzinga Newsdesk

November 30, 7:22 AM

HC Wainwright & Co. analyst Andrew Fein initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $40.

ANNX

1 minute read

Annexon Q3 EPS $(0.93) Down From $(0.77) YoY

By Benzinga Newsdesk

November 9, 5:06 PM

Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.93) per share. This is a 20.78 percent decrease over losses of $(0.77) per share from the same period last year.

ANNX